1. Home
  2. KNSA vs MSDL Comparison

KNSA vs MSDL Comparison

Compare KNSA & MSDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • MSDL
  • Stock Information
  • Founded
  • KNSA 2015
  • MSDL 2019
  • Country
  • KNSA United Kingdom
  • MSDL United States
  • Employees
  • KNSA N/A
  • MSDL N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • MSDL
  • Sector
  • KNSA Health Care
  • MSDL
  • Exchange
  • KNSA Nasdaq
  • MSDL NYSE
  • Market Cap
  • KNSA 1.7B
  • MSDL 1.8B
  • IPO Year
  • KNSA 2018
  • MSDL N/A
  • Fundamental
  • Price
  • KNSA $26.79
  • MSDL $19.63
  • Analyst Decision
  • KNSA Strong Buy
  • MSDL Buy
  • Analyst Count
  • KNSA 5
  • MSDL 7
  • Target Price
  • KNSA $33.60
  • MSDL $21.67
  • AVG Volume (30 Days)
  • KNSA 283.3K
  • MSDL 199.5K
  • Earning Date
  • KNSA 10-29-2024
  • MSDL 01-01-0001
  • Dividend Yield
  • KNSA N/A
  • MSDL 7.62%
  • EPS Growth
  • KNSA N/A
  • MSDL N/A
  • EPS
  • KNSA N/A
  • MSDL N/A
  • Revenue
  • KNSA $338,930,000.00
  • MSDL N/A
  • Revenue This Year
  • KNSA $58.95
  • MSDL $1,597.39
  • Revenue Next Year
  • KNSA $36.22
  • MSDL $14.28
  • P/E Ratio
  • KNSA N/A
  • MSDL N/A
  • Revenue Growth
  • KNSA 20.69
  • MSDL N/A
  • 52 Week Low
  • KNSA $14.12
  • MSDL $19.05
  • 52 Week High
  • KNSA $27.92
  • MSDL $24.18
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 58.67
  • MSDL 38.61
  • Support Level
  • KNSA $23.33
  • MSDL $19.58
  • Resistance Level
  • KNSA $27.35
  • MSDL $20.29
  • Average True Range (ATR)
  • KNSA 0.89
  • MSDL 0.31
  • MACD
  • KNSA 0.15
  • MSDL -0.01
  • Stochastic Oscillator
  • KNSA 86.07
  • MSDL 7.04

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and, to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

Share on Social Networks: